← All trials
NCT04853758
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 6, 2021
- Primary completion
- Mar 1, 2023
- Completion date
- Mar 1, 2023
- First posted
- Apr 21, 2021
- Last posted
- May 7, 2021
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Sao PauloLead sponsor
- University of Sao PauloReponsible party - principal investigator
- University of Sao PauloCollaborator
- University of Sao PauloOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.